352 related articles for article (PubMed ID: 31627805)
1. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
[TBL] [Abstract][Full Text] [Related]
2. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
4. N-glycan Analysis in Molecular Medicine: Innovator and Biosimilar Protein Therapeutics.
Borza B; Hajba L; Guttman A
Curr Mol Med; 2020; 20(10):828-839. PubMed ID: 33272172
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.
Wooding KM; Peng W; Mechref Y
Curr Pharm Biotechnol; 2016; 17(9):788-801. PubMed ID: 27033511
[TBL] [Abstract][Full Text] [Related]
6. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
7. Glycan characterization of biopharmaceuticals: Updates and perspectives.
Planinc A; Bones J; Dejaegher B; Van Antwerpen P; Delporte C
Anal Chim Acta; 2016 May; 921():13-27. PubMed ID: 27126786
[TBL] [Abstract][Full Text] [Related]
8. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
[TBL] [Abstract][Full Text] [Related]
9. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
[TBL] [Abstract][Full Text] [Related]
10. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
11. Analytical detection and characterization of biopharmaceutical glycosylation by MS.
Oh MJ; Hua S; Kim U; Kim HJ; Lee J; Kim JH; An HJ
Bioanalysis; 2016 Apr; 8(7):711-27. PubMed ID: 26964748
[TBL] [Abstract][Full Text] [Related]
12. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
[TBL] [Abstract][Full Text] [Related]
13. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies.
Derenne A; Derfoufi KM; Cowper B; Delporte C; Goormaghtigh E
Anal Chim Acta; 2020 May; 1112():62-71. PubMed ID: 32334683
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
Tsuda M; Otani Y; Yonezawa A; Masui S; Ikemi Y; Denda M; Sato Y; Nakagawa S; Omura T; Imai S; Nakagawa T; Hayakari M; Matsubara K
Biol Pharm Bull; 2018 Nov; 41(11):1716-1721. PubMed ID: 30158337
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
16. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan
Puranik A; Goswami R; Sutar P; Tupe D; Rasam P; Dandekar P; Jain R
J Sep Sci; 2023 Feb; 46(3):e2200521. PubMed ID: 36463509
[TBL] [Abstract][Full Text] [Related]
18. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity.
Beyer B; Walch N; Jungbauer A; Lingg N
Biotechnol J; 2019 Apr; 14(4):e1800340. PubMed ID: 30315690
[TBL] [Abstract][Full Text] [Related]
19. A rapid method for relative quantification of
Segu Z; Stone T; Berdugo C; Roberts A; Doud E; Li Y
MAbs; 2020; 12(1):1750794. PubMed ID: 32249667
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Biologic Therapeutic N-Glycan Preparation Techniques and Analytical Methods for Facilitating Biomanufacturing Automation.
Tiwold EK; Gyorgypal A; Chundawat SPS
J Pharm Sci; 2023 Jun; 112(6):1485-1491. PubMed ID: 36682489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
